Another approach is exemplified by allosteric (from the Greek, meaning “other shape”) modulators, drugs that act on targets at sites other than the native ligand binding site. Such modulators commonly target neurotransmitter receptors or ion channels; lidocaine, for example, is an allosteric modulator of sensory neuron sodium channels and nicotinic cholinergic receptor channels.26 While no examples of glucocorticoid allosteric modulators are currently available, the numbers of endogenous co-factors and chaperones implicated in glucocorticoid signaling13 would suggest that this might be a likely avenue for future drug development.